Loading...
XSTOXINT
Market cap15mUSD
Dec 23, Last price  
0.31SEK
1D
-4.91%
1Q
-35.95%
Jan 2017
-92.05%
IPO
-94.83%
Name

Xintela AB

Chart & Performance

D1W1MN
XSTO:XINT chart
P/E
—
P/S
2,260.46
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
48.77%
Rev. gr., 5y
-45.54%
Revenues
78k
010,028757,0003,0002,0001,628,00038,00000078,000
Net income
-54m
L-18.32%
-2,278,496-3,007,651-11,559,000-18,060,000-21,945,000-26,274,000-43,548,000-52,924,000-58,932,000-66,217,000-54,083,000
CFO
-53m
L+34.51%
-3,012,000-4,149,000-9,535,000-17,402,000-14,371,000-31,205,000-30,895,000-21,330,000-42,892,000-39,489,000-53,116,000
Earnings
May 08, 2025

Profile

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.
URL
https://www.xintela.se/
IPO date
Mar 22, 2016
Employees
25
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
78
 
Cost of revenue
59,029
76,223
58,483
Unusual Expense (Income)
NOPBT
(58,951)
(76,223)
(58,483)
NOPBT Margin
Operating Taxes
(4,284)
(6,948)
14,838
Tax Rate
NOPAT
(54,667)
(69,275)
(73,321)
Net income
(54,083)
-18.32%
(66,217)
12.36%
(58,932)
11.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
51,790
45,359
34,734
BB yield
-45.52%
-51.57%
-10.79%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
8,846
Net debt
(7,809)
(8,343)
(9,959)
Cash flow
Cash from operating activities
(53,116)
(39,489)
(42,892)
CAPEX
(104)
(111)
(1,255)
Cash from investing activities
(104)
(27,525)
(1,202)
Cash from financing activities
51,790
64,562
20,434
FCF
(51,449)
(71,470)
(66,824)
Balance
Cash
7,809
8,343
9,941
Long term investments
18
Excess cash
7,805
8,343
9,959
Stockholders' equity
(345,547)
(300,143)
(238,767)
Invested Capital
349,927
305,521
242,579
ROIC
ROCE
EV
Common stock shares outstanding
419,869
179,671
140,609
Price
0.27
-44.64%
0.49
-78.62%
2.29
-34.01%
Market cap
113,785
29.38%
87,949
-72.69%
321,995
12.66%
EV
105,976
79,606
312,040
EBITDA
(55,185)
(72,739)
(55,058)
EV/EBITDA
Interest
1,135
4,109
538
Interest/NOPBT